Exencial Wealth Advisors LLC Acquires 276 Shares of Icon Plc $ICLR

Exencial Wealth Advisors LLC raised its holdings in shares of Icon Plc (NASDAQ:ICLR) by 1.9% during the second quarter, Holdings Channel.com reports. The fund owned 14,656 shares of the medical research company’s stock after buying an additional 276 shares during the period. Exencial Wealth Advisors LLC’s holdings in Icon were worth $2,132,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ICLR. SVB Wealth LLC purchased a new position in shares of Icon during the first quarter valued at about $28,000. Ameritas Advisory Services LLC purchased a new position in Icon in the second quarter worth about $48,000. LRI Investments LLC purchased a new position in Icon in the second quarter worth about $49,000. Blue Trust Inc. boosted its position in shares of Icon by 44.0% during the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after buying an additional 120 shares during the period. Finally, Bruce G. Allen Investments LLC boosted its position in shares of Icon by 1,772.7% during the second quarter. Bruce G. Allen Investments LLC now owns 412 shares of the medical research company’s stock valued at $60,000 after buying an additional 390 shares during the period. 95.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. UBS Group boosted their target price on Icon from $170.00 to $240.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Truist Financial boosted their target price on Icon from $187.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Robert W. Baird boosted their target price on Icon from $222.00 to $224.00 and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a research note on Wednesday, October 8th. Finally, Cowen reaffirmed a “hold” rating on shares of Icon in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $210.64.

Icon Stock Performance

Icon stock opened at $192.60 on Thursday. The company has a 50 day moving average price of $178.56 and a 200-day moving average price of $158.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $284.98. The company has a market capitalization of $15.55 billion, a PE ratio of 19.81, a P/E/G ratio of 2.96 and a beta of 1.23.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.08. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. Icon had a net margin of 9.82% and a return on equity of 10.95%. Icon’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.75 earnings per share. As a group, equities analysts forecast that Icon Plc will post 13.38 earnings per share for the current year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.